

FIRST PRENATAL VISIT (6 - 10 weeks)	11 - 14 WEEKS GESTATION	18 - 22 WEEKS GESTATION	GESTATIONAL DIABETES MELLITUS (GDM) * DCPNS 2021
<ul style="list-style-type: none"> <li>Hemoglobin / Platelets</li> <li>ABO/Rh(D) and antibody screen</li> <li>Urine C&amp;S</li> <li>Hepatitis B Antigen</li> <li>Syphilis serology</li> <li>HIV screen (considered standard of care; counsel and inform of risks/benefits of screen and the right of refusal).</li> <li>Rubella: screen if immune status is unknown. Vaccination advised post-partum if nonimmune.</li> <li>Varicella: screen if no history of infection, vaccination, or positive serology. Vaccination advised post-partum if non-immune.</li> <li>TSH / Serum Ferritin if indicated (see indications on back)</li> <li>GDM screen *</li> <li>Gonorrhea and chlamydia: screen if at risk (e.g., age &lt; 25 years, previous STI's, new sexual partner, etc.)</li> <li>Cervical cytology if indicated (as per NS Cervical Screening Guidelines).</li> <li>1st trimester dating U/S between 8-12 weeks ideally <sup>SOGC 2023</sup> to confirm gestational age, viability, number of fetuses, early anatomic assessment, and chorionicity in multiples (plus or minus nuchal translucency (NT) as MST not applicable for multiples).</li> <li>Genetic risk screen: consult Maritime Medical Genetics (MMG) prn.</li> </ul>	<p><b>Cell Free DNA (NIPT)</b></p> <ul style="list-style-type: none"> <li>Discuss NIPT with all pregnant persons; however, it is provincially funded only for those with a high-risk screening result for Trisomy 21 in lieu of invasive testing. The testing will be offered to patients when they are seen by Maternal Fetal Medicine (MFM) or MMG and after being identified as high risk through maternal serum testing (MST).</li> <li>If a patient wants NIPT in lieu of standard screening, or after a low-risk screening result, the testing is available by self-pay through an independent referral laboratory. <b>These patients should NOT have further MST.</b> <a href="#">Self-Pay-NIPT</a> <a href="#">NIPT Information for Care Providers</a></li> </ul> <p><b>Early Maternal Serum Testing:</b></p> <ul style="list-style-type: none"> <li>Offer early MST to all pregnant persons regardless of age. <b>Note:</b> 2<sup>nd</sup> trimester testing must be done along with 1<sup>st</sup> trimester testing for an integrated screen.</li> </ul> <p><b>Early Pregnancy Review (EPR):</b></p> <ul style="list-style-type: none"> <li>Offer to pregnant persons with specific risk factors and those &gt; 35 years of age at the EDD. An EPR, conducted at the FATC at the IWK, is an ultrasound to review viability, dates, early development and assess for fetal abnormalities, through specific markers, particularly a nuchal translucency. An EPR is best used in conjunction with the MST for assessment of risk for Trisomy 21.</li> </ul> <p style="text-align: center;"><b>14 - 22 WEEKS GESTATION</b></p> <p><b>2<sup>nd</sup> trimester MST:</b></p> <ul style="list-style-type: none"> <li>Offer to all pregnant persons regardless of age.</li> </ul> <p><b>Integrated Maternal Serum Test (IMST):</b></p> <ul style="list-style-type: none"> <li>Incorporates maternal age and 1<sup>st</sup> and 2<sup>nd</sup> trimester MST into an integrated assessment of risk for fetal chromosomal abnormalities, open fetal defects, and placental abnormalities.</li> </ul> <p><b>Integrated Prenatal test:</b></p> <ul style="list-style-type: none"> <li>IMST with EPR included in the integration.</li> </ul>	<p><b>2<sup>nd</sup> trimester U/S</b></p> <ul style="list-style-type: none"> <li>Offer to all pregnant persons.</li> <li>Includes fetal biometry, amniotic fluid volume, placentation, anatomical review for anomalies, and markers for fetal aneuploidy.</li> </ul> <p style="text-align: center;"><b>24-28 WEEKS GESTATION</b></p> <ul style="list-style-type: none"> <li>Hemoglobin / Platelets</li> <li>Repeat antibody screen</li> </ul> <p>If Rh (D) <b>Negative:</b> Repeat antibody screen at 26-28 weeks BEFORE giving WinRho®SDF at 28 - 29<sup>+6</sup> weeks.</p> <p><b>WinRho®SDF is not required if the baby's father is documented to be Rh(D) negative.</b> Refer to <a href="#">Rh Guidelines</a></p> <ul style="list-style-type: none"> <li>Syphilis serology</li> <li>HIV (re)screen if high risk</li> <li>GDM screen **</li> <li>Tdap vaccine: 27-32 weeks</li> </ul> <p style="text-align: center;"><b>35-37 WEEKS GESTATION</b></p> <ul style="list-style-type: none"> <li>Group B strep</li> <li>Gonorrhea and chlamydia</li> </ul> <p style="text-align: center;"><b>Complete EACH Trimester</b></p> <ul style="list-style-type: none"> <li>EPDS (Anxiety / Depression screen)</li> <li>W-AST (Intimate partner violence (IPV) screen)</li> <li>T-ACE (Alcohol screen)</li> </ul>	<p>All pregnant persons should be screened with a HbA1c with their 1<sup>st</sup> trimester bloodwork.</p> <p><b>Add fasting plasma glucose (FPG) for those with renal disease, a hemoglobinopathy, or strong risk factors:</b> prediabetes, previous GDM, multiple gestation, BMI &gt; 40 kg/m<sup>2</sup>, PCOS, corticosteroid use, glycosuria, or high-risk population (Indigenous, Hispanic, South Asia, Asian, African Canadian)</p> <p style="text-align: center;"><b>INITIAL GDM SCREEN *</b></p> <p><b>HbA1c plus or minus FPG</b></p> <ul style="list-style-type: none"> <li>HbA1c ≥ 6.5% and/or FPG ≥ 7 mmol/L = overt diabetes or GDM*</li> <li>HbA1c ≥ 5.7% and/or FPG ≥ 5.3mmol/L = GDM*</li> <li>HbA1c &lt; 5.7% and/or FPG &lt; 5.3 mmol/L = lower risk for GDM, repeat screen at 24-28 weeks</li> </ul> <p style="text-align: center;"><b>24-28 WEEKS GDM SCREEN (PREFERRED) **</b></p> <p><b>Random 50g 1-hour GCT</b></p> <ul style="list-style-type: none"> <li>1-hour venous plasma glucose VPG ≥ 11.1 mmol/L = GDM*</li> <li>1-hour VPG &lt; 7.8 mmol/L = no GDM</li> <li>1-hour VPG 7.8 -11.0 mmol/L = proceed to 75-g oral glucose tolerance test (OGTT). <ul style="list-style-type: none"> <li>Fasting VPG ≥ 5.3 mmol/L = GDM*</li> <li>1 hour ≥ 10.6 mmol/L = GDM*</li> <li>2-hour ≥ 9 mmol/L = GDM*</li> </ul> </li> </ul> <p style="text-align: center;"><b>24-28 WEEKS GDM SCREEN (ALTERNATE) **</b></p> <p><b>HbA1c and FPG</b></p> <ul style="list-style-type: none"> <li>HbA1c ≥ 5.7% and/or FPG ≥ 5.3mmol/L = GDM *</li> <li>HbA1c &lt; 5.7% and/or FPG &lt; 5.3 mmol/L = no GDM</li> </ul> <p>* <b>GDM diagnosis: No further testing required.</b> Refer immediately to local specialty diabetes team for nutrition plan; physical activity; self-monitoring of blood glucose. <a href="#">GDM screening in NS</a></p>

PREECLAMPSIA: RISK FACTORS <small>NICE 2023</small>	PRETERM BIRTH: RISK FACTORS <small>NICE 2022 SOGC 2020</small>	INDICATIONS for ↑ FETAL SURVEILLANCE <small>ACOG 2021 SOGC 2023</small>	DISCUSSION TOPICS
<p><b>High Risk</b></p> <ul style="list-style-type: none"> <li>History of Hypertensive disease in pregnancy (HDP)</li> <li>Chronic kidney disease</li> <li>Systemic lupus erythematosus (SLE)</li> <li>Antiphospholipid antibody syndrome (APS)</li> <li>Type 1/2 diabetes</li> <li>Chronic hypertension</li> </ul> <p><b>Moderate Risk</b></p> <ul style="list-style-type: none"> <li>First pregnancy</li> <li>Age ≥ 40 years</li> <li>Pregnancy interval &gt; 10 years</li> <li>BMI ≥ 35 kg/m<sup>2</sup></li> <li>Family history of preeclampsia</li> <li>Multifetal pregnancy</li> </ul> <p><b>Consult OBS</b> if history of previous preeclampsia or strong clinical markers of ↑ risk of hypertension.</p> <ul style="list-style-type: none"> <li>Establish gestational age, baseline BP, and lab values (e.g., creatinine, liver function, urinary protein creatinine ratio).</li> <li>Initiate <b>low-dose aspirin</b> (81-162 mg/day) starting before 16 weeks and stopping by 36 weeks for those with a high-risk factor for preeclampsia or with more than 1 moderate risk factor. <small>SOGC 2022</small></li> <li>Closely monitor BP and weight gain.</li> <li>Consider calcium supplements (1 gram / day) for those with low calcium intake.</li> </ul>	<ul style="list-style-type: none"> <li>Previous preterm birth</li> <li>Cervical surgery</li> <li>Cervical insufficiency</li> <li>Uterine anomaly / surgery</li> <li>ART</li> <li>Poor nutrition</li> <li>Low socioeconomic status</li> <li>Abuse (IPV)</li> <li>Age &lt; 17 or &gt; 40</li> <li>Physical labor</li> <li>+ fFN 22 - 34 weeks</li> <li>Interpregnancy interval &lt; 6 months</li> <li>Poly/Oligohydramnios</li> <li>BMI &lt; 18 kg/m<sup>2</sup></li> <li>Diabetes</li> <li>Hypo/hyper thyroid</li> <li>Black or Indigenous</li> <li>Mental illness</li> <li>&lt; grade 12 education</li> <li>Substance use</li> <li>Poor prenatal care</li> <li>Infections</li> <li>Fetal anomaly</li> <li>Vaginal bleeding</li> <li>Multiple gestation</li> <li>Short cervical length</li> <li>PPROM</li> <li>Periodontal disease</li> </ul> <p><b>Consult OBS</b></p> <p><b>Vaginal progesterone therapy (VPT)</b> for those with a short cervical length in current pregnancy (≤ 25 mm by transvaginal U/S between 16 – 24 weeks) or with a previous PTB.</p> <p><b>Daily dose:</b> 200 mg for single pregnancy / 400 mg for multiple pregnancy, initiated between 16–24 weeks gestation (whenever risk is identified).</p> <p>VPT can be <b>continued up to 34–36 weeks</b> gestation (considering individual risk factors).</p>	<p><b>Weekly at 32 weeks</b></p> <ul style="list-style-type: none"> <li>Twins: MCDA</li> <li>Pre-existing diabetes: poor glycemic control</li> <li>SLE</li> <li>APS</li> <li>Sickle cell disease</li> <li>Renal/cardiac disease: unstable</li> <li>Rh Iso-immunization</li> <li>Previous 3rd trimester loss</li> <li>Previous IUGR or preeclampsia requiring preterm delivery</li> <li>Thrombophilia: high risk <u>1</u></li> </ul> <p><b>to 2 times per week</b></p> <ul style="list-style-type: none"> <li>IUGR (&lt; 5th percentile)</li> <li>Post-term (&gt; 41 weeks)</li> <li>Preeclampsia</li> </ul> <p><b>ASAP and prn</b></p> <ul style="list-style-type: none"> <li>↓ fetal movement</li> <li>MVA / Trauma / IPV</li> </ul> <p><b>Weekly at 36 weeks</b></p> <ul style="list-style-type: none"> <li>Twins: DCDA</li> <li>Pre-existing diabetes: good glycemic control</li> <li>Abnormal MST</li> <li>Renal/cardiac disease: stable</li> <li>ART</li> <li>BMI ≥ 40 / Age &gt; 40</li> <li>GDM treated with insulin</li> <li>Thrombophilia: low risk</li> <li>Velamentous cord insertion</li> <li>Single umbilical artery</li> <li>Alcohol use (≥ 5 drinks/week)</li> </ul> <p><b>Weekly from Dx</b></p> <ul style="list-style-type: none"> <li>PPROM</li> <li>Gestational hypertension</li> <li>Chronic abruption</li> <li>Oligohydramnios</li> <li>Polyhydramnios</li> <li>Cholestasis</li> <li>IUGR</li> </ul> <p><b>Consult OBS when increased fetal surveillance is indicated</b> or if risk of fetal demise is identified and delivery for perinatal benefit would be considered.</p> <p>The list of indications suggesting enhanced fetal surveillance is not exhaustive and are suggestions only. Individualization about when to offer antenatal fetal surveillance is advised.</p>	<ul style="list-style-type: none"> <li><input type="checkbox"/> Vitamins / iron</li> <li><input type="checkbox"/> Nutrition counselling / GWG</li> <li><input type="checkbox"/> Food safety</li> <li><input type="checkbox"/> ID precautions (e.g., pets)</li> <li><input type="checkbox"/> Hot tubs / Saunas</li> <li><input type="checkbox"/> Seat belts / Air bags</li> <li><input type="checkbox"/> Course of care / emergency contact</li> <li><input type="checkbox"/> TOLAC counseling prn</li> <li><input type="checkbox"/> Physical / sexual activity</li> <li><input type="checkbox"/> Pelvic floor health</li> <li><input type="checkbox"/> Prenatal education / resources</li> <li><input type="checkbox"/> Immunization status</li> <li><input type="checkbox"/> Early pregnancy loss: signs and symptoms, what to do</li> <li><input type="checkbox"/> Signs of preterm labour / preeclampsia / PPROM</li> <li><input type="checkbox"/> Work / parental Leave</li> <li><input type="checkbox"/> Fetal growth / movement</li> <li><input type="checkbox"/> Birth expectations: fears, family adjustment, support person(s)</li> <li><input type="checkbox"/> Late pregnancy symptoms</li> <li><input type="checkbox"/> Normal stages of labour / when to call care provider</li> <li><input type="checkbox"/> Pain relief options in labour</li> <li><input type="checkbox"/> Potential interventions / blood products</li> <li><input type="checkbox"/> Post-dates management / induction / cervical ripening</li> <li><input type="checkbox"/> Infant feeding plan</li> <li><input type="checkbox"/> Skin-to-skin / nursing</li> <li><input type="checkbox"/> Newborn care (e.g., vit K)</li> <li><input type="checkbox"/> Length of stay / discharge plan</li> <li><input type="checkbox"/> Postpartum contraception</li> <li><input type="checkbox"/> Postpartum depression</li> </ul>
<b>INDICATIONS for SERUM FERRITIN</b> <small>UK Guideline 2019</small>	<b>INDICATIONS for THYROID STIMULATING HORMONE (TSH) SCREEN</b> <small>ACOG 2021 CADTH 2016</small>		
<p><b>Anemic:</b> known haemoglobinopathy/prior IV iron replacement.</p> <p><b>Non-anemic with high risk of iron deficiency anemia:</b> Previous anemia; ≥ Para 3; Multiple pregnancy; Interpregnancy interval &lt;1 year; poor dietary habits; vegetarian/vegan diet; Age &lt; 20 years; recent history of clinically significant bleeding.</p> <p><b>Non-anemic when serum ferritin might be necessary:</b> high risk of bleeding during pregnancy or at birth, those declining blood products or those whom providing compatible blood is challenging.</p>	<ul style="list-style-type: none"> <li>+ thyroid peroxidase Ab</li> <li>History of thyroid dysfunction</li> <li>Family history of thyroid disease</li> <li>S&amp;S of thyroid dysfunction</li> <li>Recurrent miscarriages or PTB</li> <li>Infertility</li> <li>Goiter</li> </ul>	<ul style="list-style-type: none"> <li>Age &gt; 30 years</li> <li>Use of amiodarone / lithium / radiologic contrast</li> <li>Type 1 Diabetes</li> <li>Autoimmune disorder</li> <li>Resides in an area of moderate / severe iodine insufficiency</li> </ul>	<ul style="list-style-type: none"> <li>BMI ≥ 40 kg/m<sup>2</sup></li> <li>Thyroid surgery</li> <li>Head or neck radiation</li> </ul> <p><b>TSH normal range</b></p> <p>1st Trimester: 0.1 - 2.5 mU/L            2nd Trimester: 0.2 - 3.0 mU/L            3rd Trimester: 0.3 - 3.0 mU/L</p>